Loading news...
Mediolanum International Funds Ltd boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 56.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 137,675 shares of the biotechnology company's stock after purchasing an additional 49,534 shares during the quarter.
BioMarin Pharmaceuticals recently announced it is acquiring Amicus Therapeutics for $4.8B, adding two rare disease assets with blockbuster potential and strategic synergies. The acquisition provides insurance against competitive threats to Voxzogo, BMRN's key growth driver facing pressure from Ascendis and BridgeBio pipeline advances. The deal is initially slightly dilutive to 2026 non-GAAP EPS but is expected to be substantially accretive from 2027 as synergies and expansion opportunities materialize.
BioMarin expects strong sales for its rare-disease drug, Voxzogo, in Q4. The company also has several important catalysts on the way in the first half of the year.
SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes").
SAN RAFAEL, Calif., Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").
Campbell and CO Investment Adviser LLC cut its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 75.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,213 shares of the biotechnology company's stock after selling 56,336 shares during
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Five low price-to-book stocks stand out for 2026, as undervalued valuations and solid growth outlooks put them on investors' radar.
As markets reel from policy uncertainty, UHS, PNC, GPN, and BMRN emerge as compelling value picks with strong cash flow.
BioMarin Pharmaceutical (NASDAQ: BMRN) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline strategic priorities for 2026, provide preliminary 2025 revenue figures, and highlight a slate of upcoming regulatory and clinical catalysts. Chief Executive Officer Alexander Hardy said the company has been "transforming BioMarin" over the past 24 months and is targeting
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) und BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) gaben eine langfristige Unternehmensvereinbarung bekannt, die auf
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 44th Annual J.P.
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) y BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) anunciaron un acuerdo empresarial a largo plazo que se basa en su
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies PLEASANTON, Calif., and SAN RAFAEL, Calif.